TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21656668

Group type: EXPERIMENTAL
Intervention: high in iTFA (10.2 g/2500 kcal)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: high in rTFA (10.2 g/2500 kcal)
Number of subjects: 38

Group type: COMPARATOR
Intervention: control diet low in TFA (2.2 g/2500 kcal)
Number of subjects: 38
Study: 19653484

Group type: EXPERIMENTAL
Intervention: Symbol elevation (0.040 to 0.080 mm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rough features
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing tactile maps (generally 0.5 mm or higher)
Number of subjects: 0
Study: 17591024

Group type: EXPERIMENTAL
Intervention: lamivudine (100 mg daily)
Number of subjects: 139

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 139
Study: 15527191

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11254839

Group type: EXPERIMENTAL
Intervention: Electric impedance monitoring
Number of subjects: 16
Study: 9532988

Group type: EXPERIMENTAL
Intervention: 75 mg controlled‐release aspirin
Number of subjects: 3647

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3647
Study: 8023080

Group type: EXPERIMENTAL
Intervention: Workplace visits by labour inspectors (LIs)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Inspection notices (INs) issued to employers
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (no visits by LIs)
Number of subjects: 195
Study: 2916435

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 791536

Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31895308

Group type: EXPERIMENTAL
Intervention: VHA and non‐VHA hospitals
Number of subjects: 365942

Group type: COMPARATOR
Intervention: Low-performing hospitals
Number of subjects: 365942
Study: 31390451

Group type: EXPERIMENTAL
Intervention: Conventional 3 x 3 plain retainer (0.8‐mm orthodontic wire, bonded to the canines only)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Braided retainer (0.2 x 0.7‐mm stainless steel wire, bonded to all anterior teeth)
Number of subjects: 15
Study: 28342988

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) received culinary-based workshops, monthly newsletters, and telephone calls incorporating Motivational Interviewing.
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (CG) received monthly nutritional brochures from the American Institute for Cancer Research.
Number of subjects: 153
Study: 26056183

Group type: COMPARATOR
Intervention: Paclitaxel with bevacizumab (90 mg/m2)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (150 mg/m2)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Ixabepilone (16 mg/m2)
Number of subjects: 799
Study: 23470570

Group type: EXPERIMENTAL
Intervention: Speed group (n=14)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Motion group (n=15)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Speed and motion group (n=13)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 42
Study: 21749214

Group type: EXPERIMENTAL
Intervention: Genetic testing for Alzheimer's disease risk assessment
Number of subjects: 276
Study: 18246327

Group type: EXPERIMENTAL
Intervention: Quetiapine augmentation (25 to 400 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo augmentation
Number of subjects: 50
Study: 16524854

Group type: EXPERIMENTAL
Intervention: Women's Wellness Program (multimodal intervention)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal activities)
Number of subjects: 90
Study: 12967072

Group type: EXPERIMENTAL
Intervention: P60/EBS‐Multi
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: P60/One‐Step
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: P60/Prompt
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pertac/EBS‐Multi
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pertac/One‐Step
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pertac/Prompt
Number of subjects: 30

Group type: COMPARATOR
Intervention: P60/control
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pertac/control
Number of subjects: 30
Study: 10713750

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (HN019) supplemented milk
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo control (milk alone)
Number of subjects: 25
Study: 9379382

Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 91

Group type: COMPARATOR
Intervention: PMMA IOL
Number of subjects: 91
Study: 1544128

Group type: EXPERIMENTAL
Intervention: Commercially prepared kits, accessed a total of 69 times.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nursing protocol developed by RNs, accessed a total of 102 times.
Number of subjects: 26
Study: 3936343

Group type: EXPERIMENTAL
Intervention: Partial hospital setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cost of treatment
Number of subjects: 0
Study: 31235239

Group type: EXPERIMENTAL
Intervention: CDC Concussion Awareness video
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CDC Concussion Fact Sheet for Parents
Number of subjects: 140
Study: 29107589

Group type: EXPERIMENTAL
Intervention: Intravenous metamizole ± opioids (n = 23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Opioids alone (control group, n = 20)
Number of subjects: 43
Study: 27129479

Group type: EXPERIMENTAL
Intervention: Coping-motivated alcohol use
Number of subjects: 3957

Group type: EXPERIMENTAL
Intervention: High-risk subtype of coping-motivated drinking
Number of subjects: 3957

Group type: EXPERIMENTAL
Intervention: Drinking profiles based on socio-economic background
Number of subjects: 3957
Study: 24739073

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 24004

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24004

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 24004
Study: 23006444

Group type: EXPERIMENTAL
Intervention: Sirolimus (conversion group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Azathioprine (control group)
Number of subjects: 15
Study: 20569973

Group type: EXPERIMENTAL
Intervention: Intervention arm (providers could view updated ICS adherence information)
Number of subjects: 2698

Group type: COMPARATOR
Intervention: Control arm (providers could not view adherence information)
Number of subjects: 2698

Group type: EXPERIMENTAL
Intervention: Intervention arm (providers did not view adherence information)
Number of subjects: 2698
Study: 17991194

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total cholesterol levels
Number of subjects: 0
Study: 15064002

Group type: EXPERIMENTAL
Intervention: Therapeutic doses of MPH (methylphenidate) and amphetamines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication (stimulants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulants
Number of subjects: 0
Study: 11152799

Group type: EXPERIMENTAL
Intervention: Sheath group (sheath introduced immediately after puncture)
Number of subjects: 842

Group type: COMPARATOR
Intervention: Control group (diagnostic catheter introduced without sheath)
Number of subjects: 842

Group type: COMPARATOR
Intervention: Control group (crossover due to bleeding)
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Sheath group
Number of subjects: 842
Study: 10838323

Group type: EXPERIMENTAL
Intervention: Triphasic norgestimate/EE-containing oral contraceptive (ORTHO TRI‐CYCLEN(R))
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study: 7936332

Group type: COMPARATOR
Intervention: Amlodipine 10 mg/day (Group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day and hypocaloric diet (Group B)
Number of subjects: 32
Study: 2678584

Group type: EXPERIMENTAL
Intervention: Serum PAI‐1 levels above 550 ng/ml
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Serum PAI‐1 levels below 550 ng/ml
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients dying within a week after onset of shock (not having a rapidly fatal underlying disease)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 1093648

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sulfamethoxazole (SMX)
Number of subjects: 26
Study: 31519285

Group type: EXPERIMENTAL
Intervention: Grounded flaxseed (GF; 30 g/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO; 10 g/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 29678137

Group type: EXPERIMENTAL
Intervention: Group physical therapy program for knee osteoarthritis (Group PT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assisted early mobility for hospitalized older veterans (STRIDE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of helping invested family members improve veteran experiences study (iHI‐FIVES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complexity science‐based implementation intervention to promote team readiness (CONNECT)
Number of subjects: 0
Study: 26304854

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy with S-1 plus cisplatin (CRSC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Concurrent radiotherapy with cisplatin alone (CRC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both groups (CRSC and CRC)
Number of subjects: 72
Study: 25079864

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22532102

Group type: EXPERIMENTAL
Intervention: Pedometer plus computer-tailored step advice intervention (n = 45)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard condition (pedometer-only intervention, n = 47)
Number of subjects: 92
Study: 20601207

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 400 mcg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ipratropium 80 mcg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 18049436

Group type: EXPERIMENTAL
Intervention: Qigong training for one month
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 16215365

Group type: EXPERIMENTAL
Intervention: prone-CV
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: prone-HFOV
Number of subjects: 39

Group type: COMPARATOR
Intervention: supine-HFOV
Number of subjects: 39
Study: 11867492

Group type: EXPERIMENTAL
Intervention: Discriminant function categorization of risk
Number of subjects: 319

Group type: COMPARATOR
Intervention: Standard self-report measure (EAT)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Clinical interview
Number of subjects: 319
Study: 10674880

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 390

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 390
Study: 7628056

Group type: EXPERIMENTAL
Intervention: 160‐mg sachets
Number of subjects: 12

Group type: COMPARATOR
Intervention: 160‐mg tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: sachets
Number of subjects: 12

Group type: COMPARATOR
Intervention: tablets
Number of subjects: 12
Study: 1958434

Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg day‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg day‐1)
Number of subjects: 15
Study: 6261948

Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide
Number of subjects: 43

Group type: COMPARATOR
Intervention: Hexamethylmelamine and cyclophosphamide
Number of subjects: 43
Study: 30951521

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (20 mg, intramuscular injections every 28 days for 3 years)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution, intramuscular injections every 28 days for 3 years)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27372803

Group type: EXPERIMENTAL
Intervention: Food assistance intervention
Number of subjects: 904

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 904
Study: 26537789

Group type: EXPERIMENTAL
Intervention: Reablement (10 weeks of multicomponent home-based rehabilitation)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 61
Study: 25171125

Group type: EXPERIMENTAL
Intervention: Radiofrequency dissection
Number of subjects: 39

Group type: COMPARATOR
Intervention: Knot tying technique
Number of subjects: 39
Study: 22259064

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sleep (control)
Number of subjects: 12
Study: 20122369

Group type: EXPERIMENTAL
Intervention: quetiapine 300 mg/d
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: quetiapine 600 mg/d
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: lithium 600 to 1800 mg/d
Number of subjects: 802

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 802
Study: 17493294

Group type: EXPERIMENTAL
Intervention: Computer assisted CBT (6 weeks)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Therapist-directed CBT (12 weeks)
Number of subjects: 186
Study: 15759021

Group type: EXPERIMENTAL
Intervention: Calcium and potassium supplementation
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 12000814

Group type: EXPERIMENTAL
Intervention: Early elective surgery
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Surveillance by ultrasonography
Number of subjects: 1090
Study: 9988362

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Amitriptyline 150 mg/day
Number of subjects: 66
Study: 7788458

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Traditional case management
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no particular services)
Number of subjects: 90
Study: 2152752

Group type: EXPERIMENTAL
Intervention: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + surgery therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + radiotherapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + chemotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: surgery therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: radiotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 90
Study: 6941699

Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis (cranial radiation and intrathecal chemotherapy)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy siblings (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis at a young age
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Leukemia patients without central nervous system prophylaxis
Number of subjects: 24
Study: 30821335

Group type: EXPERIMENTAL
Intervention: Participatory organizational intervention (2×2 hour workshops)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Participatory organizational intervention
Number of subjects: 625
Study: 28166788

Group type: EXPERIMENTAL
Intervention: Intervention group (n=128) received DVD puppet shows shown for five consecutive days in school and a minimum of once in the home.
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (n=125) did not receive the intervention.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Intervention group (n=128) at follow-up.
Number of subjects: 253
Study: 25605660

Group type: EXPERIMENTAL
Intervention: Infancy-onset dietary intervention aiming at reducing saturated fat intake
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 512
Study: 23413981

Group type: EXPERIMENTAL
Intervention: Coronary sinus Reducer implantation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sham implantation
Number of subjects: 124
Study: 17237444

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (IT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unvaccinated individuals (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vaccinated patients (IT)
Number of subjects: 30
Study: 15111232

Group type: EXPERIMENTAL
Intervention: Novel melodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiar melodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency judgments
Number of subjects: 0
Study: 10740160

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9361338

Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg daily)
Number of subjects: 7
Study: 8245284

Group type: EXPERIMENTAL
Intervention: Coping modelling problem solving (CMPS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mastery modelling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 50
Study: 2880767

Group type: EXPERIMENTAL
Intervention: Pivampicillin 350 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Pivampicillin and Metronidazole
Number of subjects: 81
Study: 31074640

Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical mitral valve replacement
Number of subjects: 0
Study: 27105466

Group type: EXPERIMENTAL
Intervention: Corticosteroid + lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 0
Study: 26461064

Group type: EXPERIMENTAL
Intervention: Nurse-led medicines' monitoring using the West Wales ADR Profile for Mental Health Medicines
Number of subjects: 41
Study: 23512619

Group type: EXPERIMENTAL
Intervention: Group behavioral weight loss intervention
Number of subjects: 0
Study: 19819677

Group type: EXPERIMENTAL
Intervention: Red wine (30 g/ethanol/d for 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gin (30 g/ethanol/d for 28 days)
Number of subjects: 40
Study: 19624858

Group type: EXPERIMENTAL
Intervention: Lower limb intervention group (individualised programs of weight‐bearing balance and strengthening exercises)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Upper limb/cognition group (exercises aimed at management and improvement of function of the affected upper limb and cognition)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Both intervention groups (weekly group‐based exercises and a home program for twelve months)
Number of subjects: 350
Study: 16412251

Group type: EXPERIMENTAL
Intervention: Knowledge translation strategy using expert opinion leaders and local opinion leaders with a toolkit and formal continuing medical education sessions.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Formal continuing medical education session led by expert opinion leader for colorectal cancer.
Number of subjects: 42
Study: 14751699

Group type: EXPERIMENTAL
Intervention: Active corticosteroid inhaler (doubling the dose)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo corticosteroid inhaler (no change in dose)
Number of subjects: 390
Study: 11751734

Group type: EXPERIMENTAL
Intervention: Standard treatment (n=11)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Double the ACE inhibitor dose (n=11)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Standard treatment with angiotensin II antagonist (losartan, 50 mg/d; n=11)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Standard treatment with bicycle training for 30 minutes, 3 times a week (n=11)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 44
Study: 9296425

Group type: EXPERIMENTAL
Intervention: Granisetron 5 microg/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Granisetron 10 microg/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Granisetron 20 microg/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Granisetron 2 microg/kg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 200
Study: 8111223

Group type: EXPERIMENTAL
Intervention: Brofaromine (85 mg/day)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Imipramine (87 mg/day)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 189

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 189
Study: 3024864

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade) 4 mg four times daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade)
Number of subjects: 41
Study: 30587918

Group type: EXPERIMENTAL
Intervention: Generic irbesartan 150 mg
Number of subjects: 177

Group type: COMPARATOR
Intervention: Branded irbesartan
Number of subjects: 177
Study: 27543534

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Type I Block
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Type II Block
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Transmuscular Quadratus Lumborum Block
Number of subjects: 5
Study: 23876091

Group type: EXPERIMENTAL
Intervention: Camera-informed condition
Number of subjects: 61

Group type: COMPARATOR
Intervention: Camera-uninformed condition
Number of subjects: 61
Study: 22779430

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy (FT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sub-therapeutic anticoagulation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 72
Study: 20507967

Group type: EXPERIMENTAL
Intervention: XX group (alpha-actinin-3 present)
Number of subjects: 19

Group type: COMPARATOR
Intervention: RR group (alpha-actinin-3 deficient)
Number of subjects: 19